pharma · Chronic Lymphocytic Leukemia · Relapsing Multiple Sclerosis · TGTX
TG THERAPEUTICS
TG THERAPEUTICS, INC.
TG THERAPEUTICS patent portfolio — 7 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560, US
- Founded
- 2011
- Employees
- 521
- Programs
- 39
- Drugs
- 23
- Patents
- 7
TG THERAPEUTICS patents
7 pharmaceutical patents indexed for TG THERAPEUTICS. 0 expire within 24 months.
TG THERAPEUTICS has 7 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 11965032
Anti-CD20 antibody compositions
granted -
US 11884740
Anti-CD20 antibody compositions
granted -
US 11814439
Anti-CD20 antibody compositions
granted -
US 11807689
Anti-CD20 antibody compositions
granted -
US 10966977
Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders
granted -
US 10729768
Combination of anti-CD20 antibody and PI3 kinase selective inhibitor
granted -
US 9694071
Combination of anti-CD20 antibody and PI3 kinase selective inhibitor
granted
Frequently asked questions
How many patents does TG THERAPEUTICS have?
7 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do TG THERAPEUTICS patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.